145 related articles for article (PubMed ID: 38151993)
1. Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.
Ma Z; Gu Q; Dai Y; Wang Q; Shi W; Jiao Z
Cancer Sci; 2024 Mar; 115(3):820-835. PubMed ID: 38151993
[TBL] [Abstract][Full Text] [Related]
2. SHCBP1 regulates STAT3/c-Myc signaling activation to promote tumor progression in penile cancer.
Mo M; Tong S; Yin H; Jin Z; Zu X; Hu X
Am J Cancer Res; 2020; 10(10):3138-3156. PubMed ID: 33163262
[TBL] [Abstract][Full Text] [Related]
3. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
[TBL] [Abstract][Full Text] [Related]
4. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
[TBL] [Abstract][Full Text] [Related]
5. EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation.
Yin H; Zhang C; Wei Z; He W; Xu N; Xu Y; Li T; Ren K; Kuang Y; Zhu X; Yuan F; Yu H; Gou X
Cell Death Dis; 2022 Jan; 13(1):39. PubMed ID: 35013128
[TBL] [Abstract][Full Text] [Related]
6. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer.
Yang C; Hu JF; Zhan Q; Wang ZW; Li G; Pan JJ; Huang L; Liao CY; Huang Y; Tian YF; Shen BY; Chen JZ; Wang YD; Chen S
Genomics; 2021 Mar; 113(2):827-842. PubMed ID: 33515675
[TBL] [Abstract][Full Text] [Related]
7. SHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell line.
Feng W; Li HC; Xu K; Chen YF; Pan LY; Mei Y; Cai H; Jiang YM; Chen T; Feng DX
Gene; 2016 Aug; 587(1):91-7. PubMed ID: 27129942
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of SHCBP1 Inhibits Proliferation, Migration, and Invasion in Human Nasopharyngeal Carcinoma Cells.
Zhang T; He X; Yu G; He Z
Evid Based Complement Alternat Med; 2021; 2021():8262502. PubMed ID: 34484405
[TBL] [Abstract][Full Text] [Related]
9. SHCBP1 promotes cisplatin induced apoptosis resistance, migration and invasion through activating Wnt pathway.
Zou A; Wu A; Luo M; Zhou C; Lu Y; Yu X
Life Sci; 2019 Oct; 235():116798. PubMed ID: 31472149
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous XIAP and cIAP1/2 inhibition by a dimeric SMAC mimetic AZD5582 induces apoptosis in multiple myeloma.
Kikuchi S; Sugama Y; Takada K; Kamihara Y; Wada A; Arihara Y; Nakamura H; Sato T
J Pharmacol Sci; 2024 Jan; 154(1):30-36. PubMed ID: 38081681
[TBL] [Abstract][Full Text] [Related]
11. SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with poor prognosis.
Peng C; Zhao H; Song Y; Chen W; Wang X; Liu X; Zhang C; Zhao J; Li J; Cheng G; Wu D; Gao C; Wang X
J Exp Clin Cancer Res; 2017 Oct; 36(1):141. PubMed ID: 29020987
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of SHCBP1 promotes migration and invasion in gliomas by activating the NF-κB signaling pathway.
Zhou Y; Tan Z; Chen K; Wu W; Zhu J; Wu G; Cao L; Zhang X; Zeng X; Li J; Zhang W
Mol Carcinog; 2018 Sep; 57(9):1181-1190. PubMed ID: 29745440
[TBL] [Abstract][Full Text] [Related]
13. AZD5582, an IAP antagonist that leads to apoptosis in head and neck squamous cell carcinoma cell lines and is eligible for combination with irradiation.
Kadletz L; Enzenhofer E; Kotowski U; Altorjai G; Heiduschka G
Acta Otolaryngol; 2017 Mar; 137(3):320-325. PubMed ID: 27739348
[TBL] [Abstract][Full Text] [Related]
14. Biological functions and therapeutic potential of SHCBP1 in human cancer.
Lin Y; Cai H
Biomed Pharmacother; 2023 Apr; 160():114362. PubMed ID: 36739763
[TBL] [Abstract][Full Text] [Related]
15. EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.
Su K; Yuan Q; Hou H; Ke C; Huang C; Li S; Sun J; Yuan X; Lin Y; Chen Y; Xin H; Liang X; Du Z; Yuan Z
J Mol Med (Berl); 2022 Apr; 100(4):629-643. PubMed ID: 35247069
[TBL] [Abstract][Full Text] [Related]
16. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway.
Qiu J; Feng M; Yang G; Su D; Zhao F; Liu Y; Tao J; Luo W; Zhang T
Heliyon; 2023 Jun; 9(6):e17194. PubMed ID: 37484321
[TBL] [Abstract][Full Text] [Related]
17. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
18. Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zhu J; Lv J; Chen J; Zhang X; Ji Y
Cell Cycle; 2020 Nov; 19(21):2851-2865. PubMed ID: 33064959
[No Abstract] [Full Text] [Related]
19. Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
Peng C; Zhao H; Chen W; Song Y; Wang X; Li J; Qiao Y; Wu D; Ma S; Wang X; Gao C
Oncotarget; 2016 Oct; 7(41):66822-66834. PubMed ID: 27572315
[TBL] [Abstract][Full Text] [Related]
20. Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.
Huang C; He Y; Sun J; Yuan Q; Li S; Hou H; Su K; Ke C; Du Z; Yuan Z
Acta Histochem; 2022 Feb; 124(2):151856. PubMed ID: 35077998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
